Close menu

August 11th, 2023 | 08:00 CEST

Viva Gold Corp., Novo Nordisk, Vonovia - Gold Rush in Nevada - Dampened mood in Bochum

  • Mining
  • Gold
  • RealEstate
  • Pharma
Photo credits:

Viva Gold Corporation is reporting promising progress at its Tonopah Gold Project. Drilling to date proves that the Company can expand new, shallow, high-grade zones of gold mineralization in the Nevada area. For those searching for affordable housing in Germany, affordable living space has become the new gold in recent years. In light of the latest quarterly results, Group CEO Rolf Buch says Vonovia should be charging EUR 20 rent per sqm. Affordable housing is thin on the ground in Germany. Thin is the magic word for the fat plus of the Novo Nordisk share. Since the weight loss injection Ozempic has been on the market, the share price of the Danish pharmaceutical company has been rising inexorably.

time to read: 5 minutes | Author: Juliane Zielonka
ISIN: VIVA GOLD CORP. | CA92852M1077 , NOVO-NORDISK NAM.B DK-_20 | DK0060534915 , VONOVIA SE NA O.N. | DE000A1ML7J1

Table of contents:

    Brodie Sutherland, CEO, Tocvan Ventures
    "[...] One focus will be on deposits near the surface. These would be good arguments for a quick production decision using the low-cost heap leaching method. [...]" Brodie Sutherland, CEO, Tocvan Ventures

    Full interview


    Viva Gold Corporation presents promising progress at the Tonopah gold project

    Gold as an investment is particularly attractive in times of economic downturns, as it offers the opportunity to preserve wealth and provides protection when conventional investments quickly lose value. Gold's durability makes it suitable for crisis situations where obtaining physical cash may be problematic.

    Investors should keep their eyes on Viva Gold Corporation. The Canadian explorer company has a tight capital structure with 106.7 million shares and an experienced management team and board with deep experience in gold exploration and production. The lynchpin of Viva Gold Corporation is the high-grade Tonopah Gold Project. The property runs along the prolific Walker Lane mineral trend in western Nevada, just a 20-minute drive from the town of Tonopah.

    The Tonopah Gold Project has estimated resource-limited reserves of more than 394,000 ounces in the Measured and Indicated categories and an additional 206,000 ounces in the Inferred category. The area has two clearly distinguishable populations of gold mineralization: A high-grade population (>1.0 gpt Au) associated with structural splays and breccias and a second population of lower-grade disseminated gold mineralization associated with lithological contact zones and favorable bedding horizons.

    Current results from the 2023 18-hole drill program at the Company's Tonopah Gold Project are encouraging. "Our 2022 and 2023 drill programs have been extremely successful in expanding, confirming and discovering new, shallow, high-grade zones of gold mineralization at our Tonopah Gold Project." affirms CEO James Hesketh. Drilling details can be found here.

    Vonovia - Only profitable with rent of EUR 20 per square meter

    The acute housing shortage in Germany is fuelling Vonovia's rental business. As a result, the main business segment of residential rentals has recorded a positive development. EBITDA from letting, which accounts for the largest share at around 91% of the EBITDA contribution, amounts to EUR 618.5 million (Q2 2022: EUR 560.5 million). This increase of 10.3% is largely attributable to organic growth from new construction and modernization, including the integration of Deutsche Wohnen.

    According to current data from real estate portals, demand for rental apartments remained unabated across Germany in Q2 2023. Demand for existing apartments was 30% higher than at the end of 2019, while demand for new-build rental apartments rose by as much as 90%. Rolf Buch comments: "This highlights the impact of the housing shortage and underscores the importance of new rental housing construction."

    Vonovia now reports a loss of EUR 2 billion and has higher debt than intended. There are currently no plans to issue new bonds to raise additional capital. Likewise, no capital increase is currently on the agenda, as Group CEO Rolf Buch emphasized when presenting the figures on Friday.

    Currently, rising interest rates and high construction and management costs are causing the value of apartments and houses to shrink. However, recent market surveys indicate a temporary end to the price decline. *"Our calculation still does not add up," explains Buch in an interview with WELT: "Given construction costs, including planning and land, of EUR 5,000 per square meter, we would ultimately have to charge EUR 20 in rent per square meter at 4% interest.* This is not a conducive development for the market - affordable housing is urgently needed."

    Novo Nordisk - Share price soars thanks to weight loss injection

    According to the World Health Organization (WHO), over half of Europe's adults are overweight. The Obesity Report 2022 from the WHO Regional Office for Europe states that 59% of adults are overweight. The proportion of men who are overweight is 63%, while women make up 54% of the new additions to the statistics.

    How wonderful it is to have a shot that simply melts away the pounds, allowing you to continue eating as you have been. At least that is what celebrities in Hollywood seem to think, as they embrace the magical Ozempic injection from Novo Nordisk to lose weight. The active ingredient semaglutide, with names like Ozempic, Wegovy and Mounjaro, is only intended to be used for obese people in conjunction with cognitive behavioral therapy. But the successes of the miracle injection have been mentioned at the Oscars, promoted by Elon Musk, appear in countless TikTok videos and even have a song dedicated to them.

    With an estimated annual global market for injections such as Ozempic, Wegovy and Mounjaro of up to EUR 136 billion, according to analysts at Jefferies Financial Group Inc, there are predictions that these types of drugs could become the most significant blockbusters in the pharmaceutical industry.

    This week, Novo made a significant advance when its long-awaited, five-year study called "Select" showed that Wegovy reduced the risk of heart attacks and strokes by 20% in people who are overweight or obese without diabetes, compared with placebo.

    According to studies, individuals who are severely overweight can lose about 10% to 15% of their body weight on average within about 1.5 years by using Novo Nordisk's drug. The problem, as always, is in the details. Users use the injection and lose weight. However, as soon as the drug is discontinued, weight gain starts again because users have not worked on their hunger and body image, nor have they learned anything about eating nutrient-rich food versus junk food. Since humans are creatures of habit, investors can look forward to further jumps in Novo Nordisk's share price.

    Gold remains attractive in times of economic uncertainty as a value-preserving investment and protection against the depreciation of conventional investments. Viva Gold Corporation, a Canadian exploration company, is focused on the promising Tonopah Gold Project in western Nevada. It has estimated reserves of over 394,000 ounces in the Measured and Indicated categories and 206,000 ounces in the Inferred category. Novo Nordisk is seeing success from its weight loss injection, which is getting attention in the media and on social media platforms. Analysts predict a significant market potential for drugs such as Ozempic and Wegovy. Vonovia is also in the headlines as the housing shortage in Germany boosts the rental industry. Despite rising costs and losses, affordable housing remains a pressing issue. Rising interest rates and high construction costs are influencing the real estate market and the decisions of companies like Vonovia.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Juliane Zielonka

    Born in Bielefeld, she studied German, English and psychology. The emergence of the Internet in the early '90s led her from university to training in graphic design and marketing communications. After years of agency work in corporate branding, she switched to publishing and learned her editorial craft at Hubert Burda Media.

    About the author

    Related comments:

    Commented by André Will-Laudien on September 22nd, 2023 | 07:20 CEST

    Recalculation! These are the bare figures: TUI, Saturn Oil + Gas, Deutsche Bank - Buy prices non-stop!

    • Mining
    • Oil
    • travel
    • Investments
    • Banking

    Companies do not always have good figures in their baggage. Analysts listen very carefully to the words of those in charge. Often, it is only a minor sentence that changes entire valuations. TUI is slowly approaching pre-COVID figures. Saturn Oil & Gas must backtrack slightly because of substantial forest fires in Alberta, and Deutsche Bank aims to finalize the Postbank project in 2023. All three stocks offer good buying opportunities because the long-term prospects are quite convincing.


    Commented by Juliane Zielonka on September 22nd, 2023 | 06:50 CEST

    Cardiol Therapeutics, BioNTech, BYD - At top speed to new markets

    • Biotechnology
    • Pharma
    • Electromobility

    Cardiol Therapeutics is enjoying a remarkable development. The biotech company is now rolling out its ARCHER patient recruitment trial internationally at 35 participating centers. This accelerates research in the development of their therapy to combat myocarditis, a heart inflammation which has been associated with COVID-19 vaccination. For Cardiol Therapeutics, this represents an opportunity to get its therapy approved as an orphan drug. Approval is also at stake for BioNTech. With a multimillion-dollar funding boost, the Company is working on accelerated approval for a vaccine against a virus that caused quite a stir last year. The shortened development time is likely to impress investors. While business nations agree on fighting viruses, they disagree on commodities for the road. The EU would prefer to restrict BYD's successful sales on domestic roads - by imposing tariffs. BYD, meanwhile, is tapping into a completely different market.


    Commented by Nico Popp on September 21st, 2023 | 07:00 CEST

    Turnaround cancelled? Where 100% is possible: Varta, BYD, Manuka Resources

    • Mining
    • Vanadium
    • PreciousMetals
    • Batteries
    • Electromobility

    When soccer players move to a better team, it usually comes with higher earnings. Sometimes, the training is more intense, and the tasks off the pitch are more extensive. It is no longer comparable to the idyllic life at their former club. Athletes are then faced with the question, "Give up or bite the bullet?" The situation is similar for battery pioneer Varta, which is implementing its e-car plans with Porsche, of all companies. The sports car manufacturer offers major growth opportunities but is also considered meticulous among engineers. We highlight Varta's stock, take a look at BYD and outline opportunities at a company many have never heard of!